158 related articles for article (PubMed ID: 26608671)
1. Evaluation of drug-drug interaction between henagliflozin, a novel sodium-glucose co-transporter 2 inhibitor, and metformin in healthy Chinese males.
Wang L; Wu C; Shen L; Liu H; Chen Y; Liu F; Wang Y; Yang J
Xenobiotica; 2016 Aug; 46(8):703-8. PubMed ID: 26608671
[TBL] [Abstract][Full Text] [Related]
2. No apparent pharmacokinetic interactions were found between henagliflozin: A novel sodium-glucose co-transporter 2 inhibitor and glimepiride in healthy Chinese male subjects.
Que L; Huang K; Xiang X; Ding Y; Chu N; He Q
J Clin Pharm Ther; 2022 Aug; 47(8):1225-1231. PubMed ID: 35362180
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and Pharmacodynamic Interactions Between Henagliflozin, a Novel Selective SGLT-2 Inhibitor, and Warfarin in Healthy Chinese Subjects.
He X; Liu G; Chen X; Wang Y; Liu R; Wang C; Huang Y; Shen J; Jia Y
Clin Ther; 2023 Jul; 45(7):655-661. PubMed ID: 37451912
[TBL] [Abstract][Full Text] [Related]
4. Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Henagliflozin, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter 2, in Healthy Subjects Following Single- and Multiple-dose Administration.
Zhang YF; Liu YM; Yu C; Wang YT; Zhan Y; Liu HY; Zou JJ; Jia JY; Chen Q; Zhong DF
Clin Ther; 2021 Feb; 43(2):396-409. PubMed ID: 33454124
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Drug-Drug Interaction Between Henagliflozin and Hydrochlorothiazide in Healthy Chinese Volunteers.
Chen Q; Yu C; Wu Q; Song R; Liu Y; Feng S; Yu C; Jia J
Drug Des Devel Ther; 2024; 18():1855-1864. PubMed ID: 38828023
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Pharmacodynamics of Henagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus.
Yong X; Wen A; Liu X; Liu H; Liu YP; Li N; Hu T; Chen Y; Wang M; Wang L; Dai X; Huang J; Li J; Shen H
Clin Drug Investig; 2016 Mar; 36(3):195-202. PubMed ID: 26692004
[TBL] [Abstract][Full Text] [Related]
7. Effects of Food and Multiple-dose Administration on the Pharmacokinetic Properties of HR20033, a Sustained-release Formulation of Henagliflozin and Metformin for the Treatment of Diabetes, in Healthy Chinese Volunteers.
Liu Y; Huyan X; Zhang Q; Qing H; Zhang Q; Wang X; Li Y; Liu Z; Hu W
Clin Pharmacol Drug Dev; 2023 Apr; 12(4):376-384. PubMed ID: 36408821
[TBL] [Abstract][Full Text] [Related]
8. Effects of Food on the Pharmacokinetic Properties and Mass Balance of Henagliflozin in Healthy Male Volunteers.
Chen ZD; Chen Q; Zhu YT; Zhang YF; Zhan Y; Chen XF; Liang X; Jia JY; Yu C; Liu HY; Zou JJ; Liu YM; Zhong DF
Clin Ther; 2021 Sep; 43(9):e264-e273. PubMed ID: 34366153
[TBL] [Abstract][Full Text] [Related]
9. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
Kasichayanula S; Liu X; Shyu WC; Zhang W; Pfister M; Griffen SC; Li T; LaCreta FP; Boulton DW
Diabetes Obes Metab; 2011 Jan; 13(1):47-54. PubMed ID: 21114603
[TBL] [Abstract][Full Text] [Related]
10. Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Weng J; Zeng L; Zhang Y; Qu S; Wang X; Li P; Fu L; Ma B; Ye S; Sun J; Lu W; Liu Z; Chen D; Cheng Z; Liu H; Zhang T; Zou J
Diabetes Obes Metab; 2021 Aug; 23(8):1754-1764. PubMed ID: 33769656
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Pharmacokinetic Interactions Between the New SGLT2 Inhibitor SHR3824 and Valsartan in Healthy Chinese Volunteers.
Huang Y; Liu R; Wang Y; Liu G; Wang C; Chen X; Jia Y; Shen J
Clin Ther; 2022 Jul; 44(7):945-956. PubMed ID: 35778161
[TBL] [Abstract][Full Text] [Related]
12. Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor.
Fediuk DJ; Nucci G; Dawra VK; Cutler DL; Amin NB; Terra SG; Boyd RA; Krishna R; Sahasrabudhe V
Clin Pharmacokinet; 2020 Aug; 59(8):949-965. PubMed ID: 32337660
[TBL] [Abstract][Full Text] [Related]
13. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
[TBL] [Abstract][Full Text] [Related]
14. Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial.
Lu J; Fu L; Li Y; Geng J; Qin L; Li P; Zheng H; Sun Z; Li Y; Zhang L; Sun Y; Chen D; Qin G; Lu W; Guo Y; Zhang Y; Liu H; Zhang T; Zou J
Diabetes Obes Metab; 2021 May; 23(5):1111-1120. PubMed ID: 33417292
[TBL] [Abstract][Full Text] [Related]
15. Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.
Hussey EK; Kapur A; O'Connor-Semmes R; Tao W; Rafferty B; Polli JW; James CD; Dobbins RL
BMC Pharmacol Toxicol; 2013 Apr; 14():25. PubMed ID: 23631443
[TBL] [Abstract][Full Text] [Related]
16. No Relevant Pharmacokinetic Drug-Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects.
Kim YK; Hwang JG; Park MK
Drug Des Devel Ther; 2021; 15():1725-1734. PubMed ID: 33953542
[TBL] [Abstract][Full Text] [Related]
17. Relative bioavailability study of linagliptin/metformin tablets in healthy Chinese subjects.
Pichereau S; Zhao X; Cui Y; Zhao S; Hohl K; Meinicke T; Friedrich C
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):582-92. PubMed ID: 26073354
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults.
Jeong SI; Kim Y; Nah JJ; Huh W; Jang IJ; Hwang JG; Lee S
Br J Clin Pharmacol; 2023 Jun; 89(6):1780-1788. PubMed ID: 36496349
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Henagliflozin in Dialysis Patients with Diabetes.
Ding L; Liu S; Yan H; Li Z; Zhou Y; Pang H; Lu R; Zhang W; Che M; Wang L; Wang Q; Fang W; Zhang M; Che X; Gu L
Clin Pharmacokinet; 2023 Nov; 62(11):1581-1587. PubMed ID: 37713096
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
Dharmalingam M; Aravind SR; Thacker H; Paramesh S; Mohan B; Chawla M; Asirvatham A; Goyal R; Shembalkar J; Balamurugan R; Kadam P; Alva H; Kodgule R; Tandon M; Vaidyanathan S; Pendse A; Gaikwad R; Katare S; Suryawanshi S; Barkate H
Drugs; 2020 Apr; 80(6):587-600. PubMed ID: 32162274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
